EVAX

Evaxion Biotech AS

3.74 USD
-0.27 (-6.62%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Evaxion Biotech AS stock is down -12.82% since 30 days ago. The next earnings date is Aug 15, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 25% of the previous 3 May’s closed higher than April.

About Evaxion Biotech AS

Evaxion Biotech A/S identifies and develops novel immunotherapies for the treatment of various cancers, bacterial diseases, and viral infections. Its proprietary AI platforms include PIONEER, an immuno-oncology platform; EDEN, a bacterial disease platform; and RAVENTM, a viral disease platform. The company develops EVX-01, a novel liposomal, peptide-based cancer immunotherapy that is in clinical Phase 1/2a trial for indications, such as metastatic and unresectable melanoma.